4-(3-aminopropionylamino)benzoic acid ethyl ester | 385370-28-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-aminopropionylamino)benzoic acid ethyl ester
• 英文别名: ethyl 4-(3-aminopropanoylamino)benzoate
• CAS: 385370-28-5
• 化学式: C₁₂H₁₆N₂O₃
• mdl: MFCD09726278
• 分子量: 236.271
• InChiKey: LTYWCBKZXUIIMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-aminopropionylamino)benzoic acid ethyl ester 、 、 三乙胺 、 2-氨基-4,6-二氯嘧啶 、 水 在 水 作用下， 以 乙醇 为溶剂， 反应 10.0h， 以to obtain 710 mg (93%) of the title compound的产率得到4-[3-(2-amino-6-chloropyrimidin-4-ylamino)-propionylamino] benzoic acid ethyl ester
  参考文献：
  名称：

  Synthesis and methods of use of pyrimidine analogues and derivatives

  摘要：

  一种嘧啶衍生物或类似物，包括一个带有氨基取代的六元杂环基团A，通过连接子L与基团B连接，其中B是一个羧酸，羧酸酯或结构为N（Y1）-D的基团，其中Y1可以是多种取代基之一，包括氢或烷基，D是增强衍生物或类似物药理效应、促进吸收或促进血脑屏障穿透的基团。基团A可以在环中有两个或三个氮原子；通常，基团A是一个嘧啶基团，环中有两个氮原子。基团B可以是多种基团之一，包括具有智力增强活性或其他生物或生理活性的基团。

  公开号：

  US20030055249A1
• 作为产物：
  描述：

  N-CBZ-beta-丙氨酸 、 苯佐卡因 以to give 4-(3-Amino-propionylamino)-benzoic acid ethyl ester, MS的产率得到4-(3-aminopropionylamino)benzoic acid ethyl ester
  参考文献：
  名称：

  Pyrrolidine derivatives

  摘要：

  本发明涉及吡咯烷衍生物及其二聚体形式和/或药学上可接受的酯和/或盐。这些化合物可用作金属蛋白酶抑制剂，例如锌蛋白酶，特别是锌水解酶，并且对于治疗与血管收缩增加相关的疾病状态是有效的。

  公开号：

  US20020049243A1

文献信息

• Synthesis and methods of use of pyrimidine analogues and derivatives
  申请人：——

  公开号：US20030055249A1

  公开（公告）日：2003-03-20

  A pyrimidine derivative or analogue comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y 1 )-D, where Y 1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption, or promotes blood-brain barrier penetration of the derivative or analogue. The moiety A can have two or three nitrogen atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two nitrogen atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

  一种嘧啶衍生物或类似物包括一种氨基取代的六元杂环基团A，通过连接物L连接到一种基团B，其中B是一种羧酸、羧酸酯，或结构为N(Y1)-D的基团，其中Y1可以是多种取代基之一，包括氢或烷基，D是一种增强药理效应、促进吸收或促进血脑屏障穿透的基团。基团A的环中可以有两个或三个氮原子；通常，基团A是一种嘧啶基团，环中有两个氮原子。基团B可以是多种基团之一，包括具有智力活性或其他生物学或生理活性的基团。
• Methods of synthesis for 9-substituted hypoxanthine derivatives
  申请人：Glasky J. Alvin

  公开号：US20050014943A1

  公开（公告）日：2005-01-20

  An improved method of synthesis of a 9-substituted hypoxanthine derivative comprises the steps of: (1) reacting aminocyanacetamide with triethyl orthoformate to form an imidoester derivative of aminocyanacetamide; (2) forming a compound having a reactive amino group on a hydrocarbyl moiety, the hydrocarbyl moiety being linked through an amide group to a physiologically active moiety or an esterified derivative of a physiologically active moiety including therein an esterified benzoyl group; (3) reacting the imidoester with the compound having the reactive amino group on the hydrocarbyl moiety to form a derivative of 5-aminoimidazole-4-carboxamide substituted at the 1-position with a hydrocarbyl moiety linked through an amide group to a physiologically active moiety including therein an optionally esterified benzoyl group; (4) forming the six-membered heterocyclic ring of the purine moiety of the hypoxanthine by reacting the derivative of 5-aminoimidazole-4-carboxamide formed in step (3) with triethyl orthoformate to form a 9-substituted hypoxanthine compound substituted at the 9-position with a hydrocarbyl moiety linked through an amide group to a physiologically active moiety including therein an optionally esterified benzoyl group; and (5) hydrolyzing the ester of the optionally esterified benzoyl group if present.

  一种改进的合成9-取代次黄嘌呤衍生物的方法，包括以下步骤：（1）将氨基氰乙酰胺与三乙基正甲酸酯反应，形成氨基氰乙酰胺的亚甲基酯衍生物；（2）形成一个具有在烃基残基上具有反应性氨基基团的化合物，该烃基残基通过酰胺基与生理活性残基或生理活性残基的酯化衍生物相连，其中包括酯化苯甲酰基团；（3）将亚甲基酯与具有在烃基残基上具有反应性氨基基团的化合物反应，形成5-氨基咪唑-4-羧酰胺的衍生物，其在1-位上取代了一个通过酰胺基与生理活性残基相连的烃基残基，其中包括可选的酯化苯甲酰基团；（4）通过将步骤（3）中形成的5-氨基咪唑-4-羧酰胺衍生物与三乙基正甲酸酯反应形成次黄嘌呤的嘌呤基团的六元杂环环，形成一个在9-位上取代了一个通过酰胺基与生理活性残基相连的烃基残基的9-取代次黄嘌呤化合物，其中包括可选的酯化苯甲酰基团；（5）水解可选的酯化苯甲酰基团的酯。
• Synthesis and methods of use pyrimidine analogues and derivatives
  申请人：——

  公开号：US20040116453A1

  公开（公告）日：2004-06-17

  A pyrimidine derivative or analogue comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y 1 )-D, where Y 1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption, or promotes blood-brain barrier penetration of the derivative or analogue. The moiety A can have two or three nitrogen atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two nitrogen atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

  一种嘧啶衍生物或类似物包括一个氨基取代的六元杂环基团A，通过连接基L与基团B相连，其中B是羧酸，羧酸酯或结构为N（Y1）-D的基团，其中Y1可以是多种取代基之一，包括氢或烷基，D是增强衍生物或类似物的药理效应，促进吸收或促进血脑屏障穿透的基团。基团A可以在环中有两个或三个氮原子；通常，基团A是嘧啶基团，环中有两个氮原子。基团B可以是多种基团之一，包括具有神经保护活性或其他生物或生理活性的基团。
• Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives
  申请人：Glasky Alvin J.

  公开号：US20120070385A1

  公开（公告）日：2012-03-22

  The present specification discloses tetrahydroindolone derivatives or analogues and methods for treating cognitive/attention deficit disorders using such tetrahydroindolone derivatives and analogues.

  本说明书公开了四氢吲哚酮衍生物或类似物，并使用这些四氢吲哚酮衍生物和类似物治疗认知/注意力缺陷障碍的方法。
• METHODS FOR TREATING COGNITIVE /ATTENTION DEFICIT DISORDERS USING TETRAHYDROINDOLONE ANALOGUES AND DERIVATIVES
  申请人：Glasky Alvin J.

  公开号：US20090192319A1

  公开（公告）日：2009-07-30

  Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivatives and analogues, particularly tetrahydroindolone derivatives or analogues in which the tetrahydroindolone derivative or analogue is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compositions for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided. The compounds used to treat and/or palliate cognitive/attention deficit disorders in general include a tetrahydroindolone derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y 1 )-D, where Y 1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring. The moiety A can be a tetrahydroindolone moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

  本文披露了使用四氢吲哚酮衍生物和类似物治疗认知/注意力缺陷障碍的方法，特别是使用四氢吲哚酮衍生物或类似物，其中四氢吲哚酮衍生物或类似物与另一物质共价连接形成双功能结合物的方法。更具体地，本文提供了治疗成人和儿童的注意力缺陷障碍和注意力缺陷多动障碍以及轻度认知障碍和痴呆症的方法和组合物。用于治疗和/或缓解认知/注意力缺陷障碍的化合物包括四氢吲哚酮衍生物或类似物，其包括一个9原子的双环基团，基团A，通过连接剂L与基团B连接，其中B是羧酸，羧酸酯或结构N（Y1）-D的基团，其中Y1可以是多种取代基之一，包括氢或烷基，D是增强衍生物或类似物的药理效应，促进吸收或血脑屏障渗透的基团。基团A具有融合到五元环的六元环。基团A可以在五元环中有一个、两个或三个氮原子。基团A可以是四氢吲哚酮基团。基团B可以是多种基团之一，包括具有诺普力活性或其他生物或生理活性的基团。